Phase II Trial of Niraparib ± Dostarlimab in Patients With Recurrent Endometrial Carcinoma

June 4-8, 2021; Online at https://conferences.asco.org/am
Niraparib plus dostarlimab yields a clinical benefit rate of 31.8% vs 20.0% with monotherapy in patients with recurrent EC enriched for platinum resistant disease.
Format: Microsoft PowerPoint (.ppt)
File Size: 453 KB
Released: June 8, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Gilead Sciences, Inc.
GlaxoSmithKline
Merck Sharp & Dohme Corp.

Related Content

Downloadable slideset updated with highlights of key gynecologic oncology studies presented at conferences throughout 2022, from Clinical Care Options (CCO)

Jubilee Brown, MD person default Elisabeth Diver, MD person default Alexandra Leary, MD, PhD Domenica Lorusso, MD, PhD David Scott Miller, MD, FACOG, FACS Angeles Alvarez Secord, MD, MHSc Released: September 26, 2022

Downloadable slideset on the role of biomarker testing and practical information on the use of targeted therapies in NSCLC for oncology nurses, from Clinical Care Options (CCO).

person default Beth Sandy, MSN, CRNP Elizabeth S. Waxman, BSN, MSN, ANP-BC Released: September 20, 2022

From Clinical Care Options (CCO), download slides reviewing contemporary systemic therapy for HCC and BTC

James M. Cleary, MD, PhD Mark Yarchoan, MD Released: September 19, 2022

7-year follow-up from phase III SOLO-1 trial of maintenance olaparib vs placebo in newly diagnosed advanced ovarian cancer, presented at ESMO 2022 and reported by Clinical Care Options (CCO)

Released: September 15, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings